stumbled onto FiercePharma :
a little preselling is a sign of a great marketer, eh? what i used to do as a computer consultant - give 'em a taste for what's possible.
uh oh, does this mean the fucking "vaccine" doesn't work? sure hope they figured out and solved the pesky "LNP toxicity with multiple injections" problem.
Patients are “likely” to need a third dose of Pfizer and BioNTech’s shot once the period of initial protection wanes, CEO Albert Bourla said in a recent interview with CVS Health Live. The comments came shortly after Pfizer posted data showing Comirnaty was 91.3% effective against symptomatic COVID-19 for up to six months in patients who'd received their second dose.
While protection remains high for those six months, it does “go down by time,” Bourla said, adding that the data stressed a “need” for re-vaccinations. He said it was currently unclear when and how frequently boosters might be required. “There will be likely a need for a third dose somewhere between six and 12 months, and then from there, there will be an annual re-vaccination.”
In a Monday note to clients, Bernstein analyst Ronny Gal wrote that his team is "not sure [Pfizer] will be right longer-term," but that the company is "making a killing now." The team projects $36 billion from the Pfizer/BioNTech COVID-19 vaccine this year, a revenue figure that would blow away all other records in pharma history.
Pfizer has not been shy about potentially raising prices as the pandemic evolves, either. After the crisis shifts from a pandemic response to endemic virus containment, Pfizer is "going to get more on price," CFO Frank D'Amelio has said.
a little preselling is a sign of a great marketer, eh? what i used to do as a computer consultant - give 'em a taste for what's possible.
uh oh, does this mean the fucking "vaccine" doesn't work? sure hope they figured out and solved the pesky "LNP toxicity with multiple injections" problem.